Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faslodex (fulvestrant) before surgery in operable primary breast cancer
NCT00010153Phase 3Terminated
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Nov 2000
- Primary completion
- Oct 2001
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of fulvestrant in breast cancer, sponsored by European Organisation for Research and Treatment of Cancer. Started Nov 2000; status: terminated.
02
Drugs
fulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00010153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00010153.